Physician profile
Robert L Venable
NPI 1750336855
$2,244.31
in general payments reported to CMS, 2019-2025
20 companies · $99.07 in 2025
The $99.07 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $376 · 2021: $423 · 2022: $294 · 2023: $274 · 2024: $398 · 2025: $99.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.72 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $356.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $202.44 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $198.10 | 2019-2025 | Breztri, Airsupra |
| Amarin Pharma, INC. | $125.19 | 2019-2021 | |
| Glaxosmithkline, LLC. | $118.51 | 2020-2021 | |
| Abbott Laboratories | $117.92 | 2022-2024 | Freestyle Libre 2 |
| Dexcom, INC. | $113.27 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $112.41 | 2019-2023 | |
| Astellas Pharma US INC | $91.30 | 2023-2025 | Veozah |
| Abbvie INC. | $63.17 | 2023 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $62.51 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $51.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $47.39 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $43.13 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.75 | 2019-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $35.88 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $17.50 | 2024 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $16.15 | 2023 | Hetlioz, Fanapt |
| Esperion Therapeutics, INC. | $12.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Venable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.